Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA polymerase–mediated RNA incorporation sites refer to the catalytic active centers within RNA polymerase enzymes where ribonucleoside triphosphates (rNTPs) are selected and covalently added to a growing RNA chain. These sites are found in various classes of polymerases, including viral RNA-dependent RNA polymerases (RdRp), eukaryotic RNA polymerase II, and mitochondrial RNA polymerase (POLRMT). In the context of drug development, these sites are the primary targets for nucleoside and nucleotide analogs, which compete with natural substrates to be incorporated into the nascent RNA strand. Once incorporated, these analogs can cause premature chain termination, lethal mutagenesis, or delayed elongation, effectively inhibiting viral replication or cellular transcription. Understanding the structural and kinetic properties of these incorporation sites is critical for designing potent antivirals and chemotherapeutic agents while minimizing off-target toxicity to human polymerases.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA polymerase–mediated RNA incorporation sites.